What is Medefil?
Medefil operates as a fully integrated specialty pharmaceutical entity, specializing in the development, manufacturing, and commercialization of prefilled flush syringes and a diverse portfolio of injectable products. Headquartered in Glendale Heights, Illinois, the company maintains a state-of-the-art facility designed to meet rigorous safety and quality standards. By focusing on critical unmet needs in patient care, Medefil bridges the gap between complex pharmaceutical manufacturing and accessible clinical application, ensuring that healthcare providers have reliable tools for patient safety and therapeutic delivery.
How much funding has Medefil raised?
Medefil has raised a total of $2.4M across 2 funding rounds:
Debt
$1M
Debt
$1.4M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.4M led by PPP
Key Investors in Medefil
PPP
Public-Private Partnership
What's next for Medefil?
With the recent influx of capital, Medefil is well-positioned to accelerate its operational footprint and enhance its research and development pipeline. The strategic focus will likely center on expanding manufacturing capacity to meet the growing demand for prefilled injectable solutions. As the company navigates the competitive landscape of specialty pharmaceuticals, this financial runway provides the necessary stability to pursue further innovation in patient-centric delivery systems, ultimately aiming to improve clinical outcomes and operational efficiencies across the healthcare continuum.
See full Medefil company page
